Pharmacokinetics studies and toxicity profile of raltitrexed used by intraperitoneal route in normothermia in a pig model

Medical Science Monitor

Volumn 9, Issue 1, 2003, Pages

  Nguyen, Diem ^a   Emond, Claude ^a   Leclerc, Yves E ^a   Sherman, Igor ^b   Dubé, Pierre ^a  

^a MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^b Hôpital Maisonneuve Rosemont ^*

Author keywords

Cancer; Carcinomatosis; Intraperitoneal chemotherapy; Pig, normothermia; Raltitrexed

Indexed keywords

RALTITREXED;

ADHESION; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY TEMPERATURE; CARCINOMATOUS PERITONITIS; COLORECTAL CANCER; COMPARTMENT MODEL; CONTROLLED STUDY; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG TOXICITY; FEMALE; FIRST PASS EFFECT; INTESTINE ANASTOMOSIS; LAPAROTOMY; LIVER CONGESTION; NONHUMAN; PORTAL VEIN; SWINE; SYSTEMIC CIRCULATION; TIME SERIES ANALYSIS; VEIN CATHETERIZATION; WEIGHT REDUCTION;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BODY TEMPERATURE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; INJECTIONS, INTRAPERITONEAL; MODELS, STATISTICAL; NEOPLASMS; QUINAZOLINES; SWINE; THIOPHENES; TIME FACTORS;

EID: 0037277886     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Sugarbaker PH, Jablonski KA: Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg, 1995; 221(2): 124-32
2. Sugarbaker PH, Gianola FS, Speyer JC, Wesley R et al: Prospective, randomized trial of intravenous versus intraperitoneal 5FU in patients with advanced primary colon rectal cancer. Surgery, 1985; 98: 414-22
3. Jacquet P, Vidal-Jove J, Zhu B, Sugarbaker PH: Peritoneal carcinomatosis from gastrointestinal malignancy: Natural history and new prospects for management. Acta Chir Belg, 1994; 94(4): 191-7
4. Elias D, Dubé P, Blot F et al: Peritoneal carcinomatosis treatment with curative intent: the Institut Gustave-Roussy experience. Eur J Surg Oncol, 1997; 23: 317-21
5. de Waard JW, Whobbes T, Hendriks T: Early Post-operative 5-FU Does Not Affect the Healing of the Experimental Intestinal Anastomosis. Int J Colorect Dis, 1993; 8: 175-8
6. Moertel G et al: Levamisole and Fluorouracil for Adjuvant Therapy of Resected Colon Carcinoma. New Engl J Med, 1990; 322(6): 352-9
7. Mayer RG: Systemic Therapy for Colorectal Cancer: An Overview Sem Oncol, 1991; 188(5 suppl 7): 62-6
8. Zalcberg JR, Cunningham D et al: ZD 1694: A Novel Thymidylate Synthase Inhibitor with Substantial Activity in the Treatment of Patients with Advanced Colorectal Cancer. J C]in Oncol, 1996; 14(3): 716-21
9. Jackman AL, Farrugia WG et al: ZD 1694 (Tomudex): A New Thymidylate Synthase Inhibitor with Activity in Colorectal Cancer. Eur J Cancer, 1995; 31A(718): 1227-82
10. Clarke JS, Hanwell J, et al: Phase 1 trial of ZD 1694, A New Folate Based Thymidylate Synthase Inhibitor in Patients with Solid Tumors. J Clin Oncol, 1996; 14(5): 1495-1503
11. Cunningham D, Zalcberg JR, et al: Final results of a Randomized trial Comparing 'Tomudex' (Raltitrexed) with 5-Fluorouracil Plus Leucovorin in Advanced Colorectal Cancer. Ann Oncol, 1996; 7(9): 961-5
12. Cunningham D, Zalcberg JR et al: 'Tomudex' (ZD 1694): Results of a Randomized Trial in Advanced Colorectal Cancer Demonstrate Efficacy and Reduced Mucosis and Leucopenia. Eur J Cancer, 1995; 31A: 1945-54
13. Meropal NJ, Craven PJ et al: Metastatic Colorectal Cancer: Advanced in Biochemical Modulation and New Drug Development. Sem Oncol, 1995; 22(5): 509-24
14. McDermott BJ, van der Berg HW, Murphy RF: Nonlinear pharmacocinetics for the elimination of 5-flourouracil after intravenous administration in cancer patients. Cancer Chemother Pharmacol, 1982: 9: 173
15. Aherne GW, Ward E, Lawrence N, Dobinson D et al: Comparison of plasma and tissue levels of ZD 1684 (Tomudex), a highly polyglutamatable quinazoline thymidylate synthase inhibitor, in pre-clinical models. Br J Cancer, 1998; 77(2): 221-6
16. Newell DR: Clinical pharmacokinetics of antitumor antifolates. Semin Oncol, 1999; 26(2 Suppl 6): 74-81